Pulse Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-72.8M | $-53.6M | $-42.2M | $-58.5M | $-63.7M | $-49.9M | $-47.0M | $-37.5M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $406.0K | $512.0K | $542.0K | $690.0K | $480.0K | $430.0K | $494.0K | $645.0K |
| Amortization | $665.0K | $666.0K | $665.0K | $665.0K | $666.0K | $665.0K | $666.0K | $665.0K |
| Stock-Based Compensation | $21.5M | $13.6M | $7.2M | $5.2M | $14.6M | $10.1M | $11.3M | $12.3M |
| Net Cash from Operating Activities | $-54.1M | $-36.3M | $-33.0M | $-47.0M | $-54.1M | $-35.4M | $-34.2M | $-23.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $315.0K | $125.0K | $121.0K | $401.0K | $437.0K | $441.0K | $608.0K | $276.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-335.0K | $-125.0K | $-121.0K | $-401.0K | $7.6M | $10.0M | $-10.1M | $26.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $17.2M | $110.1M | $16.4M | $79.9M | $62.7M | $30.9M | $82.0K | $45.5M |
| Net Change in Cash | $-37.3M | $73.7M | $-16.8M | $32.5M | $16.2M | $5.6M | — | $47.7M |
| Free Cash Flow | $-54.4M | $-36.5M | $-33.2M | $-47.4M | $-54.5M | $-35.8M | $-34.8M | $-24.2M |